Ascendis Pharma A/S (ASND)

137,20 -3,90 (-2,76%) Alla chiusura: 04:00PM EDT

Ascendis Pharma A/S

Tuborg Boulevard 12
Hellerup 2900
Denmark
45 70 22 22 44
https://ascendispharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 879

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jan Moller Mikkelsen	President, CEO, Member of Executive Board & Executive Director	N/D	N/D	1960
Mr. Scott T. Smith	CFO, Executive VP & Member of Executive Board	N/D	N/D	1974
Ms. Lotte Sonderbjerg	Executive VP, Chief Administrative Officer & Member of the Executive Board	N/D	N/D	1961
Mr. Michael Wolff Jensen L.L.M.	Executive VP, Chief Legal Officer & Member of the Executive Board	N/D	N/D	1971
Mr. Mads Bodenhoff	Senior VP of Finance & Principal Accounting Officer	N/D	N/D	N/D
Mr. Timothy J. Lee	Senior Director of Investor Relations	N/D	N/D	N/D
Mr. Flemming Steen Jensen	Executive Vice President of Product Supply & Quality	N/D	N/D	1961
Dr. Kennett Sprogoe Ph.D.	Executive VP and Head of Research & Product Development	N/D	N/D	1979
Dr. Stina Singel M.D., Ph.D.	Executive VP & Head of Clinical Development for Oncology	N/D	N/D	1974
Mr. Joseph Kelly	Head of U.S. Commercial of Endocrinology	N/D	N/D	1969

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Governance aziendale

L'ISS Governance QualityScore di Ascendis Pharma A/S al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.